Anxiety Disorders
Published on 21. May 2015
Book
Paperback/Softback
528 pages
978-0-19-939512-5 (ISBN)
Description
Anxiety affects millions, manifesting as generalized anxiety disorder (GAD), obsessive compulsive disorder, panic disorder, phobias, post-traumatic-stress disorder (PTSD), and social anxiety disorder. Not only are anxiety disorders common, but they are also crippling, frequently co-occurring and predict high risk for depressive disorders. Shared mechanisms may explain the overlapping features of many anxiety disorders and account for associations with other highly-impairing conditions, such as major depression and substance use. Beyond risk for specific disorders, anxiety also predicts a number of other adverse outcomes, including suicidal behavior, medical problems, social, and economic difficulties. Conversely, disorder-specific mechanisms may also exist and explain the unique features of each syndrome. Thus, it is important to understand both shared and specific aspects of anxiety.
The Primer on Anxiety Disorders provides early-stage practitioners and trainees, as well as seasoned clinicians and researchers, with need-to-know knowledge on diagnosis and treatment. Clinical cases are used throughout the book to enhance understanding of and illustrate specific disorders, comorbid conditions and clinical issues. To facilitate an integrative approach, content allows clinicians to understand patient characteristics and tailor interventions. The integrated approach of each chapter includes recent research on genetics and neuroscience to understand the mechanisms of anxiety disorders, focusing on the forthcoming new nosology in DSM-5. Chapters further integrate innovative advances in clinical research providing research on a range of discoveries regarding biomarkers of illness, biological predictors of treatments and the effect of treatment on neurocircuitry.
The Primer on Anxiety Disorders provides early-stage practitioners and trainees, as well as seasoned clinicians and researchers, with need-to-know knowledge on diagnosis and treatment. Clinical cases are used throughout the book to enhance understanding of and illustrate specific disorders, comorbid conditions and clinical issues. To facilitate an integrative approach, content allows clinicians to understand patient characteristics and tailor interventions. The integrated approach of each chapter includes recent research on genetics and neuroscience to understand the mechanisms of anxiety disorders, focusing on the forthcoming new nosology in DSM-5. Chapters further integrate innovative advances in clinical research providing research on a range of discoveries regarding biomarkers of illness, biological predictors of treatments and the effect of treatment on neurocircuitry.
Reviews / Votes
All clinicians and clinical scientists working in anxiety disorders who would like a vision of where the field will be in 5 to 10 years should read this Primer. With three of the leading clinical investigators in the world as Editors, and with a first-rate roster of contributors covering all the latest findings from neurotransmitter underpinnings of drug treatments to the neuroscience of psychological treatments, readers can preview likely changes in diagnosis, assessment, and treatment in the years to come. Most importantly, we get a glimpse of a future in which we can individualize treatment based on a sound set of scientifically validated predictors of outcome. A must read!"- David H. Barlow PhD, ABPP, Professor of Psychology and Psychiatry, Boston University, Founder and Director Emeritus, Center for Anxiety and Related Disorders, Boston, MA The study of anxiety, once the foundational concept for all psychopathology, maps the path for the future of all psychiatric neuroscience and psychobiology, revealing the rich interplay of nature, nurture and development, and yielding therapeutic advances in psychotherapies, psychopharmacology and neurotherapeutics. The publishers, editors and authors of this volume, and the pioneering organization that has brought them together, the ADAA, have delivered a comprehensive, essential and useful volume for the field."
- Jerrold F. Rosenbaum, MD, Chief of Psychiatry, Massachusetts General Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School, Boston, MA Among the book's many strengths are its readability, the focus on the important, need-to-know material, and comprehensive summaries of cited research. * Doody's Notes *
More details
Series
Language
English
Place of publication
New York
United States
Target group
Professional and scholarly
Dimensions
Height: 254 mm
Width: 178 mm
Thickness: 28 mm
Weight
974 gr
ISBN-13
978-0-19-939512-5 (9780199395125)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Kerry Ressler | Daniel Pine | Barbara Rothbaum
Anxiety Disorders
E-Book
04/2015
1st Edition
OUP eBook
€82.99
Available for download
Kerry Ressler Daniel Pine Barbara Rothbaum | Kerry Ressler | Daniel Pine
Anxiety Disorders
E-Book
01/2015
1st Edition
Oxford University Press, USA
€82.99
Available for download
Persons
Kerry J. Ressler, Professor of Psychiatry and Behavioral Sciences at Emory University, received his B.S. degree in molecular biology from M.I.T., and his M.D./Ph.D. from Harvard Medical School. His work focuses on translational research bridging molecular neurobiology in animal models with human genetic research. His basic and clinical research examines neurobiological, molecular, genetic and behavioral processes that underlie fear related processing and Posttraumatic Stress Disorder.
Dr. Daniel S. Pine is Chief, Section on Development and Affective Neuroscience, in the National Institute of Mental Health Intramural Research Program. Since graduating from medical school at the University of Chicago, Dr. Pine has been engaged continuously in research on pediatric mental disorders. Currently, his group examines the degree to which mood and anxiety disorders in children and adolescents are associated with abnormalities in the amygdala, prefrontal cortex, and brain regions that modulate these structures.
Barbara Olasov Rothbaum, Ph.D. is a professor in psychiatry and Associate Vice Chair of Clinical Research at the Emory School of Medicine in the Department of Psychiatry and Behavioral Sciences and director of the Trauma and Anxiety Recovery Program at Emory. Dr. Rothbaum specializes in research on the treatment of individuals with anxiety disorders, particularly focusing on Posttraumatic Stress Disorder (PTSD).
Dr. Daniel S. Pine is Chief, Section on Development and Affective Neuroscience, in the National Institute of Mental Health Intramural Research Program. Since graduating from medical school at the University of Chicago, Dr. Pine has been engaged continuously in research on pediatric mental disorders. Currently, his group examines the degree to which mood and anxiety disorders in children and adolescents are associated with abnormalities in the amygdala, prefrontal cortex, and brain regions that modulate these structures.
Barbara Olasov Rothbaum, Ph.D. is a professor in psychiatry and Associate Vice Chair of Clinical Research at the Emory School of Medicine in the Department of Psychiatry and Behavioral Sciences and director of the Trauma and Anxiety Recovery Program at Emory. Dr. Rothbaum specializes in research on the treatment of individuals with anxiety disorders, particularly focusing on Posttraumatic Stress Disorder (PTSD).
Editor
MD, PhD, ProfessorMD, PhD, Professor, Center for Behavioral Neuroscience, Department of Psychiatry and Behavioral Sciences, Yerkes Research Ctr, Emory University, Atlanta, GA
MD, ChiefMD, Chief, Section on Development and Affective Neuroscience, Mood and Anxiety Disorders Program, Intramural Research Program, National Institute of Mental Health, Bethesda, MD
PhD, ProfessorPhD, Professor, Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA
Content
Foreword: Anxiety Disorders, Big Science, and Big Data: The Next Generation of Science and Practice ; Section 1: Overview of Anxiety and Related Illnesses ; 1. Anxiety and Related Disorders in DSM5. ; 2. Translational Perspectives, RDoC and Anxiety. ; Section 2: Neurobiology and Neural Circuitry of Anxiety Disorders ; 3. Neurobiology and Neuroimaging of Fear and Anxiety Circuitry. ; 4. The Genetics of Anxiety Disorders. ; Section 3: Development of Fear, Fear Pathways, and Anxiety Disorders in Children and Adolescents ; 5. Developmental Biology related to Emotion and Anxiety. ; 6. Development of Fear and its Inhibition ; 7. Involving the Family in Treatment. ; 8. Treating the College-age Patient. ; Section 4: Posttraumatic Stress and the Neurobiology of Trauma ; 9. PTSD and the Biology of the Stress Response. ; 10. Clinical Aspects of Trauma-related Anxiety and PTSD. ; Section 6: Obsessive Compulsive and Disorders of Cortical-Striatal Processing ; 11. Dissecting OCD Circuits: From Animal Models to Targeted Treatments. ; 12. Clinical aspects of Obsessive Compulsive Disorder. ; Section 7: Phobias, Fears, and Panic ; 13. The Etiology of Fear and Anxiety: The Role of Environmental Exposures. ; 14. Clinical Aspects of Social Anxiety Disorder and Specific Phobias. ; 15. Clinical aspects of Panic disorder. ; Section 8: Intersection of Medical and Anxiety Disorders ; 16. Fear, Anxiety, Avoidance, and Chronic Pain. ; 17. Detection and Treatment of Anxiety Disorders in Primary Care Settings. ; 18. Gastrointestinal Disorders, Irritable Bowel Syndrome, and Anxiety. ; 19. Anxiety Disorders and Cardiovascular Illness. ; Section 9: Intersection of Anxiety with Mood and Substance Disorders ; 20. Substance abuse and Comorbidity with Anxiety. ; 21. Comorbidity of Anxiety and Depression. ; 22. Generalized Anxiety Disorder. ; 23. Anxiety and Suicide. ; Section 10: Cognitive and Exposure Based Treatments of Anxiety Disorders ; 24. Neural Circuitry Mechanisms of Fear Extinction. ; 25. Learning Theory and Cognitive Behavioral Therapy. ; 26. Pharmacological Mechanisms of Modulating Fear and Extinction. ; Section 11: Neurotransmitter Pathways and Pharmacological Treatments of Anxiety Disorders ; 27. Stress, Anxiety, Depression and the Role of Glutamate Neurotransmission. ; 28. The Role of the Hypothalamic-Pituitary-Adrenal Axis in Anxiety Disorders. ; 29. Pharmacological Interventions for Adult Anxiety Disorders. ; Section 12: New Technologies and Approaches to Treatment ; 30. Adherence to Psychotherapy and Pharmacotherapy for Anxiety Disorders. ; 31. Computer Tools as Novel Treatment for Depression and Anxiety. ; 32. Internet-Based Treatment for Anxiety, OCD, and Related Disorders.